Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?

被引：0
|
作者：
Claire L. Jansson-Knodell
Courtney E. Harris
Edward V. Loftus
Randall C. Walker
Mark J. Enzler
Abinash Virk
机构：
[1] Indiana University,Division of Gastroenterology and Hepatology
[2] Mayo Clinic,Department of Internal Medicine
[3] Mayo Clinic,Division of Gastroenterology and Hepatology
[4] Mayo Clinic,Division of Infectious Diseases
来源：
Digestive Diseases and Sciences | 2021年 / 66卷
关键词：
Fungal infection; Infliximab; Adalimumab; Certolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：190 / 198
页数：8
相关论文
共 50 条
  • [41] Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk
    Ferguson, Lynnette R.
    Huebner, Claudia
    Petermann, Ivonne
    Gearry, Richard B.
    Barclay, Murray L.
    Demmers, Pieter
    McCulloch, Alan
    Han, Dug Yeo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (29) : 4652 - 4661
  • [42] Influence of anti-tumor necrosis factor-alpha therapy on pregnant women with inflammatory bowel disease and their children's immunity
    Lee, Ko Eun
    Jung, Sung-Ae
    Park, Sang Hyoung
    Moon, Chang Mo
    Shim, So Yeon
    Kim, Eun Soo
    Cho, Su Jin
    Kim, Seong-Eun
    Cho, Kwang Bum
    Yang, Suk-Kyun
    INTESTINAL RESEARCH, 2019, 17 (02) : 237 - 243
  • [43] Effectiveness and safety of vedolizumab in pediatric inflammatory bowel disease after failure of anti-tumor necrosis factor-alpha therapy
    Khan, R.
    Thacker, K.
    Spargo, M.
    Dutt, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 201 - 201
  • [44] Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease
    Jossen, Jacqueline
    Kiernan, Bridget D.
    Pittman, Nanci
    Dubinsky, Marla C.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (03): : 304 - 309
  • [45] Risk of Pancreatitis With Tumor Necrosis Factor-Alpha Inhibitors Among Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System
    Stobaugh, Derrick J.
    Samo, Salih
    Deepak, Parakkal
    Ehrenpreis, Eli D.
    GASTROENTEROLOGY, 2014, 146 (05) : S583 - S584
  • [46] Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review
    Alijotas-Reig, Jaume
    Esteve-Valverde, Enrique
    Ferrer-Oliveras, Raquel
    Llurba, Elisa
    Maria Gris, Josep
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2017, 53 (01) : 40 - 53
  • [47] Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review
    Jaume Alijotas-Reig
    Enrique Esteve-Valverde
    Raquel Ferrer-Oliveras
    Elisa Llurba
    Josep Maria Gris
    Clinical Reviews in Allergy & Immunology, 2017, 53 : 40 - 53
  • [48] SAFETY, EFFICACY, AND PHARMACOKINETIC BIOEQUIVALENCE OF BIOSIMILAR TUMOR NECROSIS FACTOR-ALPHA INHIBITORS COMPARED WITH THEIR REFERENCE BIOLOGICS: A SYSTEMATIC REVIEW
    Chingcuanco, F.
    Segal, J.
    Kim, S. C.
    Alexander, G. C.
    VALUE IN HEALTH, 2016, 19 (03) : A226 - A226
  • [49] Tumor necrosis factor-alpha inhibitors and acne fulminans: Friend or foe?
    Barry, Kelly K.
    Neale, Holly D.
    Hawryluk, Elena B.
    PEDIATRIC DERMATOLOGY, 2023, 40 (04) : 678 - 680
  • [50] The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
    Victoria Hernandez, Maria
    Sanmarti, Raimon
    Canete, Juan D.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) : 613 - 624
12345